ImmunoPrecise Antibodies Set To Begin Trading On Nasdaq December 30

ImmunoPrecise Antibodies (TSXV: IPA) (NASDAQ: IPA) has officially been approved for listing on the Nasdaq Global Markets. The company announced the news this morning, indicating that it will trade under the same symbol that Canadian shareholders are accustomed to, “IPA”.

Trading of ImmunoPrecise’s shares on the Nasdaq is expected to commence on December 30. The company is also expected to remain listed on the TSX Venture exchange as well, under its current symbol.

The announcement follows the firm filing the application for such listing back in September. At the time, the company indicated that it was motivated for the dual listing as a result of the desire to gain greater exposure to both retail and institutional investors in the United States as well as internationally.

ImmunoPrecise Antibodies last traded at $14.76 on the TSX Venture.


Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Market Movers: Canadian Small Cap COVID-19 Stocks Take A Beating

COVID-19 related stocks are all the rage this morning, however it appears to be for...

Monday, November 9, 2020, 10:56:07 AM

ImmunoPrecise Begins Path to NASDAQ

This morning ImmunoPrecise Antibodies Ltd (TSXV: IPA) announced they have commenced the application process to...

Thursday, September 10, 2020, 09:45:18 AM

ImmunoPrecise Posts Third Quarter Revenues of $4.0 Million

ImmunoPrecise Antibodies Ltd (TSXV: IPA), a therapeutic antibody and vaccine research company has released its...

Tuesday, March 10, 2020, 12:06:28 PM

ImmunoPrecise Repays $2.75 Million In Debt, Sees $3.8 Million In Warrants Exercised

ImmunoPrecise Antibodies (TSXV: IPA) announced this morning that it has managed to remove outstanding convertible...

Monday, July 20, 2020, 09:21:38 AM

Paul Andreola: ImmunoPrecise & Stock Picking In The Small Cap Arena – The Daily Dive

In this episode, we sat down with Paul Andreola, from Smallcap Discoveries, whom is also...

Monday, August 9, 2021, 01:30:00 PM